153 related articles for article (PubMed ID: 9516940)
41. Potentiation of the cytotoxic action of melphalan and "activated" cyclophosphamide against cultured tumor cells by centrophenoxine.
Sladek NE
J Pharmacol Exp Ther; 1977 Jan; 200(1):17-24. PubMed ID: 319221
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Hiramoto R; Ghanta V; Durant JR
Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
[TBL] [Abstract][Full Text] [Related]
43. The effect of phenobarbital on cyclophosphamide antitumor activity.
Alberts DS; van Daalen Wetters T
Cancer Res; 1976 Aug; 36(8):2785-9. PubMed ID: 1277188
[TBL] [Abstract][Full Text] [Related]
44. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer.
Williams SF; Bitran JD; Hoffman PC; Robin E; Fullem L; Beschorner J; Golick J; Golomb HM
Cancer; 1989 Jan; 63(2):238-42. PubMed ID: 2535952
[TBL] [Abstract][Full Text] [Related]
45. [Changes in clonogenic properties of bone marrow and transplantable mice tumor cells during combined use of cyclophosphane and biological response modifiers of adaptogenic origin].
Udintsev SN; Shakhov VP
Eksp Onkol; 1990; 12(6):55-6. PubMed ID: 2261879
[TBL] [Abstract][Full Text] [Related]
46. Growth and treatment of Ehrlich tumor in mice with alloxan-induced diabetes.
Pavelić K; Slijepcević M; Pavelić J; Ivić J; Audy-Jurković S; Pavelić ZP; Boranić M
Cancer Res; 1979 May; 39(5):1807-13. PubMed ID: 427813
[TBL] [Abstract][Full Text] [Related]
47. Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 3: In vivo investigations on murine C3H mammary adenocarcinoma treated with cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosphamide and irradiation with 10 MeV electrons--verification of the therapeutic results with 31P-NMR spectroscopy.
Ulmer W
Strahlenther Onkol; 1991 Sep; 167(9):553-60. PubMed ID: 1925940
[TBL] [Abstract][Full Text] [Related]
48. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
49. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
[TBL] [Abstract][Full Text] [Related]
50. High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential.
Gassmann W; Uharek L; Erbersdobler A; Glass B; Wottge HU; Schmitz N; Löffler H; Mueller-Ruchholtz W
Br J Haematol; 1991 Jul; 78(3):310-8. PubMed ID: 1908309
[TBL] [Abstract][Full Text] [Related]
51. [Combined action of antiblastoma preparations on lysozyme activity in animal organs].
Ievenko NV; Tsyganenko AIa
Antibiotiki; 1978 Feb; 23(2):153-8. PubMed ID: 415659
[TBL] [Abstract][Full Text] [Related]
52. Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after falure on melphalan.
Twiggs LB; Morrow CP
Cancer Treat Rep; 1977 Oct; 61(7):1369-71. PubMed ID: 589602
[No Abstract] [Full Text] [Related]
53. Combination therapy with CuDIPS, Tween 80 and cyclophosphamide: effects on survival and tumor incidence in SJL/J mice.
Crispens CG; Sorenson JR
In Vivo; 1990; 4(5):321-3. PubMed ID: 2133105
[TBL] [Abstract][Full Text] [Related]
54. [Effect of different regimens of chemotherapy and x-ray irradiation on the kinetics of experimental tumor growth].
Parkanskiĭ MI; Konovalova NP; Emanuél' NM
Vopr Onkol; 1975; 21(10):68-72. PubMed ID: 810969
[TBL] [Abstract][Full Text] [Related]
55. Carcinogenic potency of alkylating agents in rodents and humans.
Dedrick RL; Morrison PF
Cancer Res; 1992 May; 52(9):2464-7. PubMed ID: 1568217
[TBL] [Abstract][Full Text] [Related]
56. [Combination chemotherapy of tumors (an experimental study)].
Stukov AN
Vopr Onkol; 1975; 21(3):65-9. PubMed ID: 805499
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity.
Yu WD; Chang MJ; Trump DL; Johnson CS
Cancer Immunol Immunother; 1997 Aug; 44(6):316-22. PubMed ID: 9298933
[TBL] [Abstract][Full Text] [Related]
58. Temporary disappearance ("eclipse") of LPC-1 plasmacytoma M component synthesis following tumor cell transfer.
Frondoza CG; Trivedi SM; Humphrey RL
Cancer Res; 1979 Jul; 39(7 Pt 1):2497-500. PubMed ID: 445451
[TBL] [Abstract][Full Text] [Related]
59. [Relationship of the antitumor action of cyclophosphamide and prednisolone to the sequence of their administration and to the intervals between administrations in methylcholanthrene carcinogenesis in mice].
Ladnova GG; Gavrilova TN
Farmakol Toksikol; 1979; 42(6):666-70. PubMed ID: 499478
[TBL] [Abstract][Full Text] [Related]
60. Fifty-five percent complete remission of mammary carcinoma in mice with 5-fluorouracil and chloroquine.
Shoemaker JP
Cancer Res; 1978 Sep; 38(9):2700-2. PubMed ID: 679173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
